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Role of Metabolic Activation in the
Pathogenesis of Chemically Induced
Pulmonary Disease: Mechanism of Action
of the Lung-Toxic Furan, 4-Ipomeanol
by Michael R. BoydC
Many xenobiotics produce hepatic injury due to their metabolism in the liver to highly reactive
electrophilic intermediates which form covalent conjugates with nucleophilic cellular constitu-
ents. This presentation describes studies indicating that the production of chemically reactive
metabolites by pulmonary metabolism of xenobiotics can also play a fundamental role in the
pathogenesis ofchemically induced lung disease.
Introduction
The isolation, characterization, and chemical
synthesis of 4-ipomeanol [1-(3-furyl)-4-hydroxy-
pentanone], a toxic furanoterpenoid produced in
mold-damaged sweet potatoes, have been de-
scribed (1-5). The compound is probably the ma-
jor component of the "lung edema factor" (6) pro-
duced in sweet potatoes (Ipomoea batatas) in-
fected with the common mold, Fusarium solani.
The ingestion of mold-damaged sweet potatoes
has been implicated for many years in natural
outbreaks of poisoning in cattle. Affected animals
suffer severe and often fatal respiratory distress.
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Pathological findings are usually restricted to the
lungs. Among the typical pulmonary findings are
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edema, congestion, and hemorrhage (7). The dis-
ease has been given several descriptive names;
among these are pulmonary adenomatosis and
atypical interstitial pneumonia. The identifica-
tion of the lung edema factor provides an etio-
logical basis for this peculiar pulmonary disease.
In addition, 4-ipomeanol and other toxic compo-
nents have been detected in minimally blemished
sweet potatoes offered for sale at food markets,
although the significance of this observation is
not known (6).
Chemicals which reproducibly produce an
acute, specific pulmonary toxicity by routes ofad-
ministration other than inhalation are relatively
rare and their mechanisms of action are poorly
understood. 4-Ipomeanol, therefore, may provide
a unique tool with which to probe pathogenetic
mechanisms of chemically-induced lung disease.
An understanding of the mode of action of this
model agent may provide new insight into both
normal and abnormal pulmonary physiology as
well as into mechanisms of, and factors regulating
susceptibility to, pulmonary disease produced in
humans by drugs or other chemicals in the en-
vironment.
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FIGURE 1. Pathological responses to 4-ipomeanol in the mouse 24 hr after a 35mg/kg dose, IP: (left) massive pleural effusion (fluid
inpipet); (right) section showingprominent intra alveolar edema.
Many xenobiotics are now known to produce
liver injury after their conversion in the liver to
highly reactive intermediates. The proximate
toxins can alkylate adjacent cellular macromole-
cules and produce tissue damage (8). The reali-
zation that the lung can also metabolize some for-
eign chemicals (9-11) stimulated our interest in
the possibility that metabolic activation might
likewise be involved in the pathogenesis of cer-
tain chemically-induced lung diseases. The pur-
pose ofthis paperis tobrieflyreview recent work
from our laboratory which indicates that 4-ipome-
anol toxicity involves metabolic conversion ofthe
compound to a species which alkylates the target
tissue. The studies reviewed herein will be de-
scribed indetailinforthcomingpublications.
Toxicityof 4-lpomeanol
LDso studies were carried out with chemically
pure synthetic 4-ipomeanol prepared in our labo-
ratory (3,4). As shown in Table 1, all species
Table 1. Species and sexdifferences to toxicity of
4-ipomeanol.
Route of LDso (±S.E.),
Species Sex administration mg/kg
Mouse M Oral 38±3
Mouse M IV 21±1
Mouse M IP 36±4
Mouse F IP 28±2
Rat M IP 24 +2
Rat F IP 17±2
Rat M IV 18±5
Rabbit M IP 30 +10
Guinea pig M IP 15±5
tested are susceptible to the toxin and the char-
acteristic response is obtained regardless of the
route ofadministration.
In all animal species tested, the lung is the
primary target organ. There are, however, some
subtle differences in the way the toxicity is
Environmental HealthPerspectives 128manifested. For example, in the mouse the toxin
causes a massive pleural effusion and intraalve-
olar and perivascular edema (Fig. 1). In the rat
(Fig. 2) pleural effusion is usually minimal or ab-
sent. However, intraalveolar and perivascular
edema are pronounced, and lung damage can be
roughly quantitated by lung wet weight/body
weight or wet weight/dry weight ratios. In the
guinea pig (Fig. 3), the toxin causes a very strik-
ing response, characterized by alveolar edema
and widespread vascular hemorrhage. In all spe-
cies, these gross pathological changes are ap-
parent within 6-24 hr after the administration of
the toxin.
Studieson the Mechanism of
Action of 4-lpomeanol
Distribution and Excretion
The distribution and excretion of radiolabeled
4-ipomeanol were studied in rats after IP ad-
ministration of "4C-toxin (12). Within 24 hr, ap-
proximately half the administered radioactivity
appeared in the urine. Much smaller smounts of
radioactivity were excreted in the feces and ex-
pired air. After 96 hr only a few more percent had
appeared in the urine, while the total fecal excre-
tion had increased to 15-20°h of the administered
dose. Excretion of radioactivity into the expired
air after 96hr totaled less than 5%.
According to radiochromatography most of the
radioactivity in the urine was due to unmetabo-
lized 4-ipomeanol. Fecal radioactivity was
primarily due to unidentified metabolites of the
toxin.
The maximal accumulation of radioactivity in
the tissues occurred within the first hour,
roughly corresponding tothe rapid urinary excre-
tion phase. Peak activity in the gut (including
contents) occurred later, 2-8 hr after toxin ad-
ministration. The latter finding may reflect the
accumulation of 4-ipomeanol metabolites in the
feces in the gut. Carcass and gut contained the
greatest total percentage of radioactivity. Liver
contained a maximum of about 10% of the total
administered radioactivity, while the amounts in
lungs, kidneys, and blood reached maxima of
about 1-4%. All other tissues contained less than
1% of the administered dose. A maximum of 1-
FIGURE 2. Appearance oflungs ofaratreceiving alethal dose (30mg/kg, IP)of4-ipomeanol; (left) gross; (right)microscopic.
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FIGURE 3. Striking pulmonary congestion and hemorrhage in guinea pig given a lethal dose (30 mg/kg, IP) of 4-ipomeanol: (left)
lungsin situ in thorax; (right) lungs removedin toto.
2% of the dose was recovered from peritoneal
fluid 0.5 hr after dosing, but only traces of
radioactivity were found at later times. This sug-
gests that the administered toxin solution is
rapidly absorbed fromthe site ofinjection.
Since the total content ofradioactivity in a par-
ticular tissue depends on the total mass of the
tissue, the data were also expressed in terms of
radioactivity per gram of tissue in order to per-
mit a comparison ofthe relative concentrations of
4-ipomeanol and/or its metabolite(s) in the vari-
ous tissues. Specific activities (dpm/g wet weight
tissue) were normalized to the maximum value
obtained in lung.
As shown in Figure 4, the greatest concentra-
tion of radioactivity occurred in the lung. The
maximum concentration in gut and its contents
was 85-90% of the maximum level reached in the
lungs. Liver, kidneys, and blood contained max-
imum concentrations of 60-80% of the maximum
lung levels, while all other tissues, including
spleen, heart, thymus, adrenals, pancreas, and
brain contained less than 25% ofthe lunglevels.
Figure 4 also shows that after the peak, which
occurs in the tissues after 1-2 hr, the radioactivi-
ty declines to a relatively constant concentration
representing residual activity. The residual ac-
tivity is greatest in lung and persists at least
several days after the injection of 4-ipomeanol.
This observation led us to consider the possibility
that the toxin, or its metabolite(s), was bound or
otherwise sequestered by certain tissues, espe-
cially lung.
Other studies have shown that 70-90% of the
residual activity remaining in lung, liver, and kid-
neys after 24 hr is tightly bound to tissue macro-
molecules. Extensive organic solvent extraction
of homogenates of these tissues fails to remove
most ofthe residual activity, suggesting the bind-
ing may be covalent. Table 2 shows a comparison
of total radioactivity and nonextractable or
bound radioactivity in all the various tissues 24
hr after toxin administration. The data are ex-
pressed as nanomoles of toxin bound per gram
(wet weight) of tissue. The amount of bound ac-
tivity in lung is markedly greater than in any
othertissue.
When the bound radioactivity, shown in Table
2, was measured and expressed in terms of pro-
tein-bound toxin, the markedly preferential pul-
monary binding was again demonstrated (13). It
should be emphasized, ofcourse, that irreversible
binding to protein does not imply that protein is
necessarily the "target substance;" it is simply
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nIGURE 4. Relative concentrations ofradioactivity in tissues ofthe rat after IP administration of 10mg/kg of4-ipomeanol-3,5-'4C.
the fraction which provides the greatest recovery
of covalently bound radioactivity. It therefore
serves as a way of measuring, experimentally,
the presence, or formation, of a chemical species
sufficiently reactive to alkylate tissue macromol-
ecules.
The time courses of covalent binding, pulmo-
nary edemagenesis, and lethality have been de-
termined in the rat after administration of '1C-4-
ipomeanol (14). After a toxic dose was given IP,
the maximal level of covalently bound compound
was attained by 80 min. After intravenous ad-
ministration, covalent binding peaked in 40 min.
It therefore appears not only that the toxin is
rapidly absorbed from the peritoneal cavity, but
also that covalent binding of toxin occurs rapidly
after absorption.
On the other hand, both the pulmonary damage
and the lethality occur after the toxin is covalent-
ly bound. This of course would be expected, if
covalent binding represents an initial event in the
toxic mechanism. Lung fluid accumulation (wet
weight/dry weight ratios) peaked 16-24 hr after
toxin was given IP. Interestingly, this was the
time also at which deaths began to occur, sug-
Table 2. Comparison of total concentration of radioactivity
with concentration ofbound radioactivity in various tissues of
the rat 24hrafteradministration of4-ipomeanol-3,5-'4C.
Total radio- Bound radio-
activity activity
(± S.E.), nmole (± S.E.), nmoles
toxin/g wet weight toxin/g wet weight
Tissue tissue tissue
Lung 134±5 121±5
Liver 67 9 47 12
Kidney 41 2 30±+6
Ileum 112 19 6 2
Heart 33±21 1±1
Blood 58+8 2+1
Spleen 64 + 12 2 + 1
Adrenals 28±4 1 ± 1
Pancreas 12 ±3 0.5 + 0.5
Thymus 8± 1 0.3± 0.5
Testes 6± 1 0.1 ± 0.3
Muscle 11 ± 1 0.1 ± 0.1
Brain 5 ± 1 0.05 + 0.01
a Dose of 4-ipomeanol-3,5-14C, 10 mg/kg (0.06
mmole/kg).
gesting that lung damage was the cause ofdeath.
Animals living longer than 40 hr usually s;rnvived.
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131On the basis of these experiments, covalent
binding subsequently was measured routinely at
4 or 8 hr, and the pulmonary wet weight/dry
weight ratios were determined at 24 hr after in-
jection ofthe toxin. At these times the respective
parameters had reached their maximal levels and
remained relatively constant thereafter.
The dose dependence of covalent binding, pul-
monary edemagenesis, and lethality have also
been examined (13,14). Although the amount of
covalent binding of toxin to lung increased rel-
atively smoothly over the range ofdoses tested, a
pronounced "threshold" effect was observed in
the rate of change of the pulmonary wet weight/
dry weight ratios. Doses in the range of 2-10
mg/kg produced a slight increase in lung fluid,
while doses above 10-15 mg/kg produced a strik-
ing increase in the lung fluid accumulation.
Deaths also began to occur in the animals with
these doses, suggesting again that the lung le-
sions were the primary cause of death. The
"threshold effect" for the increase in lung fluid
may be due to a saturation of normal pulmonary
mechanisms for handling excess fluid, such as
elimination by the lymphatics (15).
Studies ofLungand LiverMicrosomal Enzymes
Which Catalyze Covalent Bindingof4-Ipomeanol
When '4C-4-ipomeanol was incubated with
various subcellular fractions of lung and liver
homogenates (in the presence of NADPH), radio-
activity became covalently bound predominantly
to the microsomal fractions (13,14). The maximal
rate of covalent binding of toxin occurred only in
the presence ofNADPH and oxygen. Binding was
strongly inhibited in the presence of a carbon
monoxide-enriched atmosphere or by addition of
cytochrome c but was not inhibited by addition of
cyanide. No binding occurred when heat-dena-
tured microsomes were used, or when the incuba-
tion was at 1-2°C. These experiments indicate
that, without prior metabolism, 4-ipomeanol is
not sufficiently reactive to alkylate tissue com-
ponents. The covalently bound radioactivity from
'4C-4-ipomeanol, therefore, must represent the
formation of a chemically reactive metabolite.
The lung and liver microsomal enzyme systems
which activate the toxin have the classic charac-
teristics of cytochrome P-450-dependent mixed-
function oxidases (MFO).
Role of Metabolism and Covalent Binding for
Toxicity of4-IpomeanolInVivo
Several important questions were apparent at
this point. First, does covalent binding of 4-
ipomeanol in vivo represent the formation of a
chemically reactive metabolite in vivo? Second, is
the formation of this metabolite responsible for
the production of the toxic lesions? And third,
given the finding that activating enzymes are
present in both lung and liver, what is the source
of the metabolite that covalently binds and dam-
ages the target tissue?
We approached these questions by examining
the effects of various inhibitors and inducers of
MFO on the metabolism, covalent binding, and
toxicity of 4-ipomeanol (13,14). It should be em-
phasized that with both inhibitors and inducers it
is difficult to predict apriori their actual effect on
a given toxicity in vivo, since they may affect
both toxifying as well as detoxifying pathways
(16). The situation is especially complex when
more than one tissue can serve as a site for both
toxication and detoxication, and when each tissue
may respond differently to a given inducer or in-
hibitor. Whatever effect a particular pretreat-
ment produces, however, the correlation between
the severity of the toxicity and the degree of
covalent binding of the toxin to the target tissue
should be maintained if the two phenomena in-
deed are related.
Pretreatments with pyrazole, piperonyl butox-
ide, and cobaltous chloride all markedly reduced
both the in vivo covalent binding and the toxicity
of 4-ipomeanol. Although both lung and liver
binding were inhibited, lung binding still pre-
dominated; lung remained the target organ when
larger doses oftoxin were given tothe pretreated
animals. In vitro studies likewise confirmed the
inhibitory effects of these compounds on micro-
somal activation of the toxin. P-Diethylamino-
ethyldiphenylpropyl acetate (SKF 525-A) inhib-
ited thein vitro metabolism and covalent binding,
but had no significant effect on the covalent bind-
ing or toxicity of 4-ipomeanol in vivo. It is likely,
therefore, that SKF 525-A inhibits detoxifying
metabolic pathways in vivo as well as toxifying
ones.
These experiments demonstrated an excellent
correlation between the degree of toxicity and
the amount of covalent binding of toxin to the
lung. Furthermore, the only effects of these
pretreatments that could satisfactorily account
for these findings were their effects of MFO ac-
tivity. It therefore appears that 4-ipomeanol tox-
icity is due to the formation of a chemically reac-
tive metabolitein vivo which can alkylate tissue.
Two types of MFO inducers, 3-methylcholan-
threne (MC) and phenobarbital (PB), were also
examined for their effects on covalent binding
Environmental Health Perspectives 132and toxicity of 4-ipomeanol (17). A very striking
phenomenon was seen with MC pretreatment. In
this group of animals, overall toxicity was
decreased, but the relative proportion ofcovalent
binding of toxin to liver was markedly increased,
whereas it was decreased in the lung. Interest-
ingly, these alterations were associated with the
appearance of widespread centrilobular hepatic
necrosis in MC-treated rats given toxic doses of
4-ipomeanol. In contrast, pulmonary damage was
minimal or absent in these animals.
In vitro covalent binding of 14C-4-ipomeanol
was increased in liver microsomes from MC-
pretreated rats, but binding to lung microsomes
was unchanged. This suggests that the increase
in hepatic toxicity of 4-ipomeanol in MC-treated
rats is due to an increased hepatic metabolism of
the compound to a chemically reactive species.
The reduction in lung binding and toxicity in
these animals appears to be due to an increased
hepatic clearance and shortened biological half-
life ofthe toxin.
PB pretreatment also increased the maximal
rate of covalent binding of toxin to liver
microsomes in vitro, but no change occurred in
binding to lung microsomes in vitro. These find-
ings indicate that 4-ipomeanol can be metabolized
by forms of cytochrome P-450 induced either by
PB or by MC. However, PB treatment did not al-
ter the target organ for covalent binding and tox-
icity of 4-ipomeanol in vivo, although it did
significantly increase the LD50 value. Covalent
binding of toxin was reduced in vivo in both lung
and liver in PB-treated animals compared to con-
trols. PB induction probably affects predominant-
ly detoxication pathwaysin vivo.
An important conclusion can be drawn from the
experiments in MC-pretreated rats. The toxic
metabolite of 4-ipomeanol is so reactive that lit-
tle, if any, of it escapes the organ in which it is
formed. It therefore appears that in normal ani-
mals the specific lung toxicity produced by 4-
ipomeanol results primarily from pulmonary me-
tabolism ofthe agent; the liver is not a significant
source of the reactive metabolite that binds to
and damages the lungs. In MC-pretreated ani-
mals, liver necrosis results from metabolic activa-
tion of4-ipomeanol by hepatic enzymes.
Nature of the Chemically Reactive Metabolite of
4-Ipomeanol: Structural Requirements for4-
Ipomeanol Toxicity
Studies, both in vitro and in vivo, indicate that
the reactive metabolite formed by MFO-cata-
lyzed metabolism of 4-ipomeanol is a highly elec-
trophilic species (13,14). Addition of the nucleo-
philic tripeptide, glutathione (GSH), or "soluble
fraction" (which contains GSH and GSH-trans-
ferases), markedly inhibited covalent binding of
4-ipomeanol in vitro, presumably by acting as an
alternate nucleophile. Depletion of endogenous
GSH, by diethyl maleate pretreatment, signifi-
cantly increased toxicity and covalent binding of
4-ipomeanol in vivo; this indicates that a reactive
electrophile is also produced in vivo from
metabolism of 4-ipomeanol and causes the tissue
lesions. As a result of these preliminary studies,
we have undertaken further investigations to
evaluate the possibility that endogenous GSH
may have a general role as a modulator of pulmo-
nary toxicities produced by many potentially
lung-toxic agents, including 4-ipomeanol. GSH is
known to play an important role in the detoxica-
tion ofseveral hepatotoxins (8).
Analogs of 4-ipomeanol, in which the furan
moiety was replaced by a phenyl or a methyl
substituent, were not metabolized to toxic elec-
trophiles in vivo or in vitro (14). Thus, the furan
component of 4-ipomeanol clearly is essential for
toxicity and covalent binding ofthe molecule. Re-
cent data from other laboratories support the
conclusion that furans are potentially reactive
materials in vivo. Swenson et al. (18) have dem-
onstrated that microsomal enzymes convert the
dihydrofuran moiety of aflatoxin B1 to a reactive
intermediate, probably an epoxide, and postu-
lated that this metabolite may be the proximate
hepatocarcinogen for aflatoxin. Mitchell et al.
(19) have shown that a series of furano com-
pounds, including furan itself and the diuretic
drug furosemide, produced hepatic and renal ne-
crosis in animals after activation ofthe furan ring
to reactive metabolites, presumably epoxides.
From our data, a reasonable candidate for an
electrophilic reactant is also a furan epoxide
formed from MFO-catalyzed metabolism of 4-
ipomeanol (Fig. 5). The simplicity of the 4-
ipomeanol molecule indeed greatly limits other
possibilities.
Development ofTolerance to 4-Ipomeanol
Toxicity
Tolerance to normally lethal doses of 4-ipome-
anol can be produced in rats by prior administra-
tion of small, nonlethal, doses of the toxin itself
(20).
This effect may result, at least in part, from a
decrease in pulmonary MFO activity which is pro-
duced by 4-ipomeanol pretreatment (21). Pre-
sumably, the amount of reactive metabolite
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FIGURE 5. Possible pathways for toxication and detoxication of
4-ipomeanol.
formed in the lung from the small pretreatment
dose is sufficient to destroy a portion of the en-
zyme system that formed it without destroying
the cells. Therefore, on subsequent challenge
with large doses of toxin, there is insufficient en-
zyme activity to form concentrations of the alkyl-
ating metabolite required to produce pathological
changes usually seen at these doses. A mecha-
nism ofthis nature has been proposed by other in-
vestigators to account for the marked tolerance
to the liver toxicity of carbon tetrachloride, pro-
duced by prior treatment with small, nonlethal
doses ofthat hepatotoxic agent (22).
A decrease in hepatic metabolism and covalent
binding of 4-ipomeanol is also seen in the 4-
ipomeanol-pretreated rats. However, the in vivo
covalent binding, although decreased in both liv-
er and lung, still is much higher in lung at all
doses tested. It is not surprising, therefore, that
sufficiently large doses of 4-ipomeanol will still
produce the usual selective pulmonary toxicity in
the "tolerant" rats.
Alterations in other biochemical parameters
may also play a role in the development of tol-
erance to 4-ipomeanol. For example, in addition
to the demonstrated decrease in enzymatic activi-
ty for metabolic activation of 4-ipomeanol, it is
possible that tolerance could also be caused by in-
creased rates of detoxication of the reactive,
metabolite. Our present studies have indicated
that no microsomal pathways for detoxication art
induced by 4-ipomeanol pretreatment in liver or
lung. Activities of nonmicrosomal pathways may
be important, however. For example, an increase
in GSH availability, and/or in activities of GSH
transferases, may allow more effective detoxica-
tion of an electrophilic metabolite of 4-ipomeanol.
In this regard, it is interesting to note that
chronic exposure oflungs to pulmonary irritants,
such as ozone, stimulates lung glucose-6-phos-
phate dehydrogenase activity (23). The increased
formation of NADPH that then occurs may in
turn increase the availability of alternate nucleo-
philic sulfhydryls by reduction of disulfide groups
(e.g., oxidized GSH to reduced GSH). Further
studies, therefore, are underway to determine
whether chronic pretreatment with 4-ipomeanol
affects GSH availability.
A cellular adaptation phenomenon may also
contribute to tolerance development to 4-
ipomeanol. Preliminary observations (24) indi-
cate that type II pulmonary alveolar cells are
substantially increased in number and size after
4-ipomeanol pretreatment. Proliferation of these
cells is a well-documented response oflung tissue
to toxic injury (25). Furthermore, Cross (26)
recently pointed out that proliferation of these
cells not only serves to repair chemically dam-
aged pulmonary tissue, but also may play a key
role in augmenting the biochemical defense
mechanisms of lung tissue against a variety of
types oftoxicdamage.
Metabolic activation, occurring in the lung,
may be an important mechanism underlying the
production of lung diseases resulting from ex-
posure to a variety of xenobiotics. Therefore,
mechanisms of tolerance induction elucidated for
4-ipomeanol may also be applicable to the well-
recognized, but poorly understood, tolerance and
cross-tolerance phenomena produced by a variety
oflung-toxic chemicals and gases (27).
Pathways forToxication and Detoxication of
4-Ipomeanol
Figure 5 shows our present workinghypothesis
of the important pathways for the toxication and
detoxication of 4-ipomeanol. Relative activities of
the various pathways shown, in both liver and
lung, may modulate susceptibility to the toxin,
and may also determine the target organ. In addi-
tion, 4-ipomeanol may be metabolized by path-
ways not involving a reactive intermediate. For
example, the side-chain hydroxyl may be a site
for conjugation with glucuronic acid; the more
readily excretable glucuronide may then appear
in feces and/or urine. On the other hand, oxida-
tion by microsomal enzymes probably produces a
highly reactive furan epoxide which can further
react by a variety of pathways. A 2,3-epoxide is
134 ~~~~~~~~~~~~~~Environmental Health Perspectives 134shown in Figure 5, but a 2,5-epoxide must also be
considered a possibility. In either case, it may
react with adjacent nucleophilic sites on tissues,
or with mobile nucleophiles like GSH. Alterna-
tively, it may rearrange nonenzymatically. One
possible rearrangement product is the corre-
sponding dialdehyde, a species which would also
be highly reactive and therefore also should be
considered a candidate for the proximate toxic
metabolite. An intermediate epoxide also may be
further metabolized by enzymes such as epoxide
hydratases. Moreover, some investigators have
found that levels of epoxide hydratase activity in
lung are much lower than in liver (28,29). Thus, a
relative deficiency of this potential detoxication
pathway in lung could play a significant role in
the pulmonary specificity of 4-ipomeanol. The
possible participation and interplay of all the
above reactions in 4-ipomeanol activation and
toxicity is under active investigation.
Whereas the liver is composed of a relatively
homogenous cell population, the lung is composed
ofmany different cell types. Therefore, an impor-
tant approach to the mechanism of pulmonary in-
jury produced by a reactive metabolite of 4-
ipomeanol will be to determine particular cell
type(s) which may be affected. A prio7i, it seems
that those cells capable of metabolizing 4-
ipomeanol to a reactive species would be most
susceptible to its toxic actions. This seems
especially likely since the toxic metabolite is very
reactive and probably interacts with cellular
nucleophiles close to its site of formation. Auto-
radiographic studies, currently in progress, may
permit the identification ofcell types to which the
toxin is binding. It will then be essential to obtain
morphological correlates of covalent binding and
cellular alterations. Another important and com-
plimentary approach will be the isolation of spe-
cific cell populations from lung and the examina-
tion oftheir ability to metabolize 4-ipomeanol to a
reactive electrophile. This approach is unfortu-
nately limited at present, since isolation of well
defined cell populations has been technically dif-
ficult. However, new and useful methods are rap-
idly becoming available (30).
Discussion and Perspective
To conclude this presentation, three importapt
points should be emphasized regarding the rele-
vance ofthe studies with 4-ipomeanol to a general
consideration of target organ toxicity. First, it is
clear that lung disease can result from the pro-
duction and interaction of chemically reactive
metabolites formed in vivo after administration
of a parent toxin by either parenteral or enteral
routes. Second, the studies with 4-ipomeanol in-
dicate that lung metabolism per se can play a
primary role in the production of the proximate
toxic metabolites. Third, when a potential toxin
can be metabolized in more than one tissue, the
target organ for toxicity is dependent upon rela-
tive rates of toxication and detoxication path-
ways available in allthe tissues.
Figure 6 is an attempt to illustrate that the
target organ of a metabolically activated toxin
may be determined by an extraordinarily com-
plex set of pharmacokinetic interactions. Only
two potential sites for metabolism of the toxin,
liver and lung, are represented.
The parent drug may be delivered to the lung
or liver after absorption from parenteral or
enteral routes. Absorption of some inhaled com-
pounds directly into the lung parenchyma may
also occur. The parent drug may be metabolized
and removed from the body by pathways which
do not involve formation of chemically reactive
intermediates. Good examples of these pathways
are the glucuronidation and sulfation of some
drugs to form more polar and more readily ex-
cretable derivatives. Such pathways are known
to be present in both liver and lung (31). Alterna-
tively, a chemically stable parent drug may be
metabolized to a chemically reactive intermedi-
ate which can produce tissue damage.
Metabolism of certain compounds by the liver
is known to produce a variety oftypes of reactive
species. The studies described herein, as well as
in other recent reports (32,33), indicate that lung
metabolism by both oxidative and reductive
pathways can convert certain xenobiotics to sev-
eral different kinds of chemically reactive spe-
cies. Also, epoxide intermediates can apparently
be formed by pulmonary metabolism of some car-
cinogens (34) as well as from bromobenzene (35),
a compound that produces bronchiolar necrosis in
rats. It is likely that many other kinds of chem-
ically reactive metabolites can be produced by
lungmetabolism ofxenobiotics.
Just as the relative rates of disposition of the
parent drug along toxifying and detoxifying met-
abolic pathways can affect the level ofreactive in-
termediate formed, the concentration of the re-
actant is also affected by its own rate of detoxica-
tion. For example, epoxide intermediates may be
detoxified by one or more of the several routes
discussed earlier. Reactive intermediates other
than epoxides likewise may have one or more
routes available for detoxication.
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FIGURE 6. Schematic representation ofsomepharmacokinetic factors that may modulate chemically induced lungdisease.
Assuming a reactive metabolite can be formed
either at hepatic or extrahepatic sites, or at both
sites, with which tissues will it interact to pro-
duce pathological changes? Some toxic interme-
diates are so reactive that they do not escape the
organ in which they are formed. The alkylating
metabolite formed from 4-ipomeanol appears to
be an example. Other proximate toxic metabo-
lites may be sufficiently stable to enter the cir-
culation and subsequently react with tissues dif-
ferent than their site of formation. For example,
bromobenzene produces both liver and lung le-
sions in rats (35); the compound can be metab-
olized to a chemically reactive species by en-
zymes present in both liver and lung. However, in
this case the toxic metabolite appears to be suffi-
ciently stable to escape the liver (35). Thus, it has
not been possible to determine the primary
source of the bromobenzene metabolite that co-
valently binds and damages the lung. It should be
re-emphasized, however, that even when a toxin
can be metabolically activated at extrahepatic
sites such as lung, metabolism in the liver may
still play a critical role in determining the target
organ for toxicity in vivo. This is clearly illus-
trated by the previously described alteration of
target organ for 4-ipomeanol toxicity, produced
by MC-pretreatment. In such cases, the much
greater mass of metabolically active tissue pro-
vided by the liver may provide a level of hepatic
clearance of the toxin such that the delivery of
unmetabolized toxin to potential extrahepatic
sites for metabolic activation is significantly
reduced. This reduction may likewise prevent the
appearance of toxic lesions in the extrahepatic
tissue.
Lung disease also apparently can result from
the formation of reactive metabolites exclusively
in the liver. For example, certain toxic pyrro-
lizidine alkaloids produce lesions in both liver and
lung. Mattocks (36) has reviewed work showing
that the liver, but not the lung, can convert these
alkaloids to reactive pyrrole derivatives which
alkylate both liver and lung. Experimentally,
these toxic pyrrolic derivatives produce "specif-
ic" pulmonary lesions only ifgiven intravenously,
into the afferent circulation of the lungs. Al-
though pyrroles can apparently alkylate tissue
macromolecules directly, it is interesting to
speculate that metabolic activation may also con-
tribute to the covalent binding of pyrroles; pyr-
roles are nitrogen analogs of furans, and it is
clear that furans can be activated by both hepatic
and pulmonary metabolism.
Whereas electrophilic metabolites have been
clearly implicated in a variety of toxicities, the
precise mechanisms whereby they produce tissue
lesions are poorly understood. It is probable,
however, that covalent binding of toxicants to
tissue macromolecules is a primary component in
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agents. The tissue lesions may result from a com-
bination of many biochemical and structural al-
terations produced by nonspecific alkylation of
cellular macromolecules. In other instances, al-
though covalent binding serves experimentally as
an index of formation of a reactive species, the
basic pathogenic process may not have a covalent
interaction of toxin and tissue as a primary com-
ponent. For example, the trichloromethyl radical
('CC13) formed in vivo by reductive cleavage of
carbon tetrachloride covalently binds to liver
tissue. However, the hepatic necrosis produced
by CCI. probably results from a chain-type perox-
idation of hepatic lipids initiated by the elec-
trophilic metabolite (37). Toxins such as 4-
ipomeanol may be ofconsiderable value in studies
ofthe molecular pathology oflungdamage caused
by chemicals. They may offer unique tools with
which to probe biochemical and morphological
correlates ofdrug-induced lungdisease.
As a final comment, many of the potential
pathways for toxication and detoxication of
xenobiotics in the lung have not been adequately
explored. Furthermore, most of the complex in-
teractions of hepatic and pulmonary metabolism,
some of which are schematically represented in
Figure 6, need much further characterization.
The precedents set by the present studies would
seem to justify the speculation that metabolic ac-
tivation may be an important mechanism underly-
ing the pathogenesis of lung disease resulting
from exposure to a variety of xenobiotics by both
parenteral and enteral routes, as well as by in-
halation. Hopefully, therefore, increased empha-
sis will be directed to these important areas ofin-
vestigation.
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